checkAd

     686  0 Kommentare Pieris Pharmaceuticals and The University of Melbourne Receive Research Grant to Advance Immunological Diseases Program - Seite 2

    Professor Stephen Smith, Dean of the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne commented, "The University of Melbourne is committed to improving the health of patients. To do this, we continue to bring outstanding scientists together with leading edge technologies to develop and commercialize innovations that represent the future treatment for diseases that are incurable and poorly controlled by conventional therapies. We are pleased to be working with Pieris to advance this innovative Anticalin-based drug candidate towards a clinical trial."

    Professor Daniel Hoyer, a veteran of Novartis Pharmaceuticals and Head of the Department of Pharmacology and Therapeutics, added, "We are very happy to be part of this endeavour and value the expanded relationship with Pieris that this grant provides. Monoclonal antibodies represented a paradigm shift in the successful treatment of numerous immune diseases, yet have their limitations. Anticalins may represent another paradigm shift by bringing the targeted approach like mAb-based therapeutics while adding benefits of local delivery."

    The grant awards a total of $AUS 564,061.50 ($444,125 USD) between January 1, 2015, and December 31, 2016, for technical and development activities on PRS-060, which is currently in preclinical development.

    About Pieris
    Pieris is a clinical-stage biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that have the potential to be safer and more effective than conventional approaches. Anticalins show promise in addressing high-unmet medical needs and expanding the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has ongoing R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan. For more information visit www.pieris.com.

    About the University of Melbourne
    Established in 1853, the University of Melbourne is a public-spirited institution that makes distinctive contributions to society in research, learning and teaching and engagement. It's consistently ranked among the leading universities in the world, with international rankings of world universities placing it as number 1 in Australia and number 33 in the world (Times Higher Education World University Rankings 2014-2015). Medical researchers at the University of Melbourne are embedded in clinical environments and the translation of research into patient treatments is significant to the University.

    Seite 2 von 3



    Verfasst von Marketwired
    Pieris Pharmaceuticals and The University of Melbourne Receive Research Grant to Advance Immunological Diseases Program - Seite 2 FREISING, GERMANY and MELBOURNE, AUSTRALIA--(Marketwired - March 30, 2015) - Pieris Pharmaceuticals, Inc. (OTCQB: PIRS) and The University of Melbourne today announced the receipt by the University of a research grant to further develop Pieris' …